resolutionbio.com Open in urlscan Pro
35.81.137.57  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * About
   * Company
   * News
   * Current Openings
 * Liquid Biopsy Assays
   * Resolution ctDx FIRST
   * Resolution ctDx Lung
   * Custom
   * Immuno-oncology
 * Science
   * Overview
   * Comprehensive
   * Patient Case Studies
   * Clinical Trials
   * Publications & Presentations
   


WE BRING YOUR CANCER INTO FOCUS

Learn How We Are Demonstrating Clinical Utility
How We Are Different Patient Case Studies


RESOLUTION BIOSCIENCE IS NOW PART OF EXACT SCIENCES


CTDX THE COMPREHENSIVE LIQUID BIOPSY PLATFORM

The ctDx platform uses next-generation sequencing (NGS) and a standard
peripheral blood sample. This non-invasive assay platform has been validated to
detect all four major types of genetic alterations known to drive cancers.
Turnaround time is measured in days, not weeks.

SNVS

INDELS

FUSIONS

CNV

Learn more about why its important to have a comprehensive test


NEWS

September 2023

AGILIENT TECHNOLOGIES AND EXACT SCIENCES AGREE TO TERMS OF SALE FOR RESOLUTION
BIOSCIENCE

Read more
March 2021

AGILENT TO ACQUIRE RESOLUTION BIOSCIENCE, STRENGTHENING LEADERSHIP POSITION IN
CANCER DIAGNOSTICS

Read more
January 2021

RESOLUTION BIOSCIENCE ANNOUNCES COMPANION DIAGNOSTIC COLLABORATION WITH MIRATI
THERAPEUTICS

Read more
September 2020

NEW NON-INVASIVE TEST FOR LUNG CANCER AVAILABLE EXCLUSIVELY FROM LABCORP

Read more
February 2020

RESOLUTION BIOSCIENCE AND LABCORP WILL COLLABORATE TO COMMERCIALIZE THE
RESOLUTION CTDX LUNG™ LIQUID BIOPSY ASSAY

Read more
October 2019

VANDERBILT ONCOLOGISTS PUBLISH RESULTS OF FIRST STUDY TO DEMONSTRATE CLINICAL
UTILITY OF RESOLUTION LIQUID BIOPSY ASSAY TO MONITOR RESPONSE AND RESISTANCE TO
ENSARTINIB

Read more
June 2019

RESOLUTION ADVANCING DEVELOPMENT OF CELL-FREE DNA COMPANION DIAGNOSTIC FOR
PROSTATE CANCER THROUGH COLLABORATION WITH JANSSEN

Read more
May 2019

RESOLUTION LIQUID BIOPSY ASSAY RECEIVES BREAKTHROUGH DEVICE DESIGNATION FROM FDA

Read more
April 2019

RESOLUTION LIQUID BIOPSY ASSAY DEMONSTRATES FEWER FALSE POSITIVES AND HIGHER
POSITIVE PREDICTIVE VALUE THAN THREE KNOWN COMMERCIAL CTDNA NGS TESTS

Read more
April 2019

GENOMEWEB — ASTRAZENECA LIQUID BIOPSY COMPARISON DETAILS CONCORDANCE FAILURES

Read more
March 2019

RESOLUTION LIQUID BIOPSY ASSAY DETECTS MORE ACTIONABLE ONCOGENIC FUSIONS WITH
HIGHER ALLELE FREQUENCY THAN GUARDANT360

Read more
March 2019

FOR SOME PEOPLE WITH CANCER, A SIMPLE BLOOD TEST CAN BE A LIFESAVER

Read more
March 2019

SMALL CELL LUNG CANCER TRANSFORMATION AS A MECHANISM OF RESISTANCE TO PD-1
THERAPY IN KRAS-MUTANT LUNG ADENOCARCINOMA: A REPORT OF TWO CASES.

Read more
February 2019

ASCO GU 2019: PHASE II STUDY OF NIRAPARIB IN PATIENTS WITH METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER AND BIALLELIC DNA-REPAIR GENE DEFECTS :
PRELIMINARY RESULTS OF GALAHAD

Read more
February 2019

CIRCULATING TUMOR DNA ANALYSIS ALLOWS RAPID THERAPY MATCHING IN LUNG CANCER

Read more
January 2019

RESOLUTION ASSAY BEING USED IN SPACEWALK STUDY

Read more
December 2018

RESOLUTION BIOSCIENCE HOLDS FOCUS ON LIQUID BIOPSY CDX, KIT DEVELOPMENT AS IT
PREPS FOR GROWTH

Read more
November 2018

A PROSPECTIVE STUDY OF CIRCULATING TUMOR DNA TO GUIDE MATCHED TARGETED THERAPY
IN LUNG CANCERS.

Read more
November 2018

LIQUID BIOPSY IS EFFECTIVE AT GUIDING TREATMENT OF LUNG CANCER, STUDY FINDS

Read more
September 2018

RESOLUTION BIOSCIENCE EARNS NEW YORK STATE APPROVAL FOR BLOOD-BASED LUNG CANCER
ASSAY

Read more
January 2018

LONGITUDINAL CELL-FREE DNA ANALYSIS IN PATIENTS WITH SMALL CELL LUNG CANCER
REVEALS DYNAMIC INSIGHTS INTO TREATMENT EFFICACY AND DISEASE RELAPSE.

Read more
More News


TUMOR EVOLUTION IN REAL-TIME

Longitudinal monitoring offers the ability to monitor tumor evolution over time
and under treatment. Allelic frequencies can change quickly. At disease
progression, it becomes critical to have a comprehensive genotype to look for
resistance mechanisms.

PATIENTS AND CLINICIANS

Patients are why we are here. We have all been touched by cancer. Helping
patients drives us to make the best diagnostics available.

RESEARCH COLLABORATORS

Clinicians stand at the frontline of care. As the director of patient care, we
work with them to provide critical information.

PHARMACEUTICALS

Treatment starts with effective therapies. We work with biotech and
pharmaceutical companies to support their clinical trials and do biomarker
discovery.

COMPANY

 * HOME

 * ABOUT

 * PRESS

ASSAYS

 * RESOLUTION CTDX FIRST

 * RESOLUTION CTDX LUNG

 * CUSTOM ASSAYS

SCIENCE

 * OVERVIEW

 * COMPREHENSIVE

 * PATIENT CASE STUDIES

 * CLINICAL TRIALS

 * PUBLICATIONS & PRESENTATIONS


© Copyright 2012-2023 Resolution Bioscience, Inc. All Rights Reserved.
Legal and Privacy